Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China

Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China

ObjectiveTo assess the cost-effectiveness of combining camrelizumab with rivoceranib versus sorafenib as initial treatment options for advanced hepatocellular carcinoma (HCC) across different developmental regions in China.MethodsUtilizing TreeAge Pro and data from the phase III randomized CARES-310...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhonghua Zhao, Xiongying Jiang, Shiping Wen, Yanzhang Hao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Oncology
Subjects:	cost-effectiveness camrelizumab rivoceranib hepatocellular carcinoma China
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1491404/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Transarterial Chemoembolization Plus Camrelizumab and Rivoceranib versus Camrelizumab and Rivoceranib Alone for BCLC Stage C Hepatocellular Carcinoma
by: Zhou WJ, et al.
Published: (2024-12-01)

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for patients with unresectable hepatocellular carcinoma: a cost–utility analysis in China and the United States
by: Qiuling Zhao, et al.
Published: (2025-05-01)

The safety and effectiveness of sintilimab versus camrelizumab, both plus targeted drugs, in advanced hepatocellular carcinoma
by: Chenglong Zhao, et al.
Published: (2025-06-01)

Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy
by: Zheng X, et al.
Published: (2025-06-01)

Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Donafenib and Camrelizumab in the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Retrospective, Single-Arm Study
by: Wu C, et al.
Published: (2025-07-01)

Case Report: Durable complete response of advanced-stage hepatocellular carcinoma to DEB−TACE combined with lenvatinib and camrelizumab
by: Baiguo Xu, et al.
Published: (2025-06-01)

Hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with sorafenib for advanced hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (Double-IA-001): a phase II trial
by: Lujun Shen, et al.
Published: (2025-05-01)

Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial
by: Kugeluke Yalikun, et al.
Published: (2025-05-01)

Use of camrelizumab in treatment of nasopharyngeal carcinoma
by: Yu. V. Alymov, et al.
Published: (2024-12-01)

Case Report: Camrelizumab plus gemcitabine followed by concurrent chemoradiation for HPV-positive and PD-L1-positive tonsillar squamous cell carcinoma
by: Xuesong Li, et al.
Published: (2025-03-01)

Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis
by: Zhiwei Zheng, et al.
Published: (2024-12-01)

Efficacy and safety of camrelizumab plus Lacticaseibacillus paracasei in the treatment of advanced esophageal squamous cell carcinoma: A single-arm, single-center, exploratory trial
by: Tengfei Zhang, et al.
Published: (2025-07-01)

Long survival after neoadjuvant and adjuvant camrelizumab plus chemotherapy and surgery in a patient with hepatoid adenocarcinoma of the lung: A case report
by: Xuhua Huang, et al.
Published: (2024-12-01)

Induction chemotherapy plus camrelizumab combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma in non-endemic areas: a phase 2 clinical trial in North China
by: Zhongqiu Wang, et al.
Published: (2025-02-01)

Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients
by: Shusheng Wu, et al.
Published: (2025-05-01)

Efficacy and safety of camrelizumab for the treatment of cervical cancer: a systematic review and meta-analysis
by: Xiaodong Mi, et al.
Published: (2024-12-01)

Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study
by: Qi Zhao, et al.
Published: (2025-08-01)

Camrelizumab, an Anti‐PD‐1 Monoclonal Antibody, Plus Carboplatin and Nab‐Paclitaxel as First‐Line Setting for Extensive‐Stage Small‐Cell Lung Cancer: A Phase 2 Trial and Biomarker Analysis
by: Jia Yu, et al.
Published: (2025-08-01)

Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA–IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial
by: Shuyu Ji, et al.
Published: (2025-07-01)

A case of camrelizumab-induced anaphylaxis and successful rechallenge: a case report and literature review
by: Ping Song, et al.
Published: (2025-03-01)

Immune repertoire sequencing reveals differences in treatment response to camrelizumab plus platinum-based chemotherapy in advanced ESCC
by: Xiaoling Zhang, et al.
Published: (2025-02-01)

Overcoming therapeutic resistance in driver-negative NSCLC: Immunomodulatory mechanisms and clinical efficacy of Camrelizumab-chemotherapy combination in a real-world cohort
by: Yan Ge, et al.
Published: (2025-06-01)

Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single‐arm, exploratory phase II trial
by: Qinglian Tang, et al.
Published: (2024-09-01)

An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti‐Angiogenic Agents for Therapy: A Case Report
by: Li Wang, et al.
Published: (2025-06-01)

Camrelizumab-based therapies for the treatment of advanced lung cancer: a prospective, open-label, multicenter, observational, real-world study
by: Dong Zhao, et al.
Published: (2025-03-01)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer: 3-year survival from a phase 2 study
by: Zhenyu Lin, et al.
Published: (2025-05-01)

Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma
by: Zhang J, et al.
Published: (2025-05-01)

Correlation Between Treatment‐Related Adverse Events and Efficacy of Camrelizumab in Combination With Apatinib in Patients With Unresectable Hepatocellular Carcinoma
by: Ting Zhang, et al.
Published: (2025-03-01)

Is non-contrast-enhanced magnetic resonance imaging cost-effective for screening of hepatocellular carcinoma?
by: Genevieve Jingwen Tan, et al.
Published: (2024-01-01)

Corrigendum: Case report: Long remission and survival following immunotherapy in a case of pulmonary pleomorphic carcinoma
by: Tongshan Wang, et al.
Published: (2024-12-01)

Sex disparities in hepatocellular carcinoma immunotherapy: hormonal and genetic influences on treatment efficacy
by: Lei Song, et al.
Published: (2025-05-01)

Disparities in Immunotherapy Use Prior to First-Line Approval for Metastatic Hepatocellular Carcinoma in the United States
by: Manav Shah, et al.
Published: (2025-02-01)

Initial treatment efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma in clinical practice
by: Tetsu Tomonari, et al.
Published: (2024-10-01)

A case report of immunotherapy-related breast reactive capillary endothelial proliferation
by: Chen JIE, et al.
Published: (2023-02-01)

Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE
by: Wu-Kui Huang, et al.
Published: (2017-01-01)

Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma
by: Binghua Li, et al.
Published: (2025-01-01)

Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma
by: Kunyuan Wang, et al.
Published: (2025-06-01)

Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
by: Young Eun Chon, et al.
Published: (2023-02-01)

Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
by: Hiroaki Kanzaki, et al.
Published: (2025-01-01)

Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial
by: Jie Li, et al.
Published: (2025-07-01)